Literature DB >> 19750066

Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.

Prakash S Masand1, Miquel Roca, Martin S Turner, John M Kane.   

Abstract

OBJECTIVE: Although many clinicians acknowledge the occurrence of adherence problems with medication regimens among patients with schizophrenia, the problem shows no sign of improving. This may be because, in thinking about the issue, clinicians have tended to focus on patients who openly refuse or repeatedly discontinue treatment. While this description applies to only a minority of patients, in our experience, full adherence is rare; most patients are only partially adherent at best. This article examines the issue of adherence behavior in schizophrenia, focusing on the impact of partial adherence on treatment outcomes, particularly early in the course of illness. We also review potential strategies for managing the problem. DATA SOURCES: Original research and review articles published in English from 1980 to 2008 were identified using the PubMed database, with the search terms schizophrenia or psychosis combined with compliance, noncompliance, partial compliance, adherence, nonadherence, or partial adherence. STUDY SELECTION: Articles were selected by the authors on the basis of the hypotheses and/or data described. DATA SYNTHESIS: Failure to adhere to medication as prescribed can have a major impact on the course of illness and treatment outcomes in patients with schizophrenia. Even relatively short gaps in medication coverage increase the risk of relapse. Problems with adherence are common early in the course of illness, when the consequences of relapse can be particularly devastating.
CONCLUSION: Clinicians in primary care and psychiatric settings need to be vigilant for signs of adherence problems among their patients and to act when necessary to prevent or alleviate the consequences of inadequate medication cover. Relapse prevention strategies, particularly for patients with early psychosis, should include ensuring that medication lapses are minimized or eliminated.

Entities:  

Year:  2009        PMID: 19750066      PMCID: PMC2736032          DOI: 10.4088/PCC.08r00612

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  72 in total

1.  Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects.

Authors:  H Verdoux; J Lengronne; F Liraud; B Gonzales; F Assens; F Abalan; J van Os
Journal:  Acta Psychiatr Scand       Date:  2000-09       Impact factor: 6.392

Review 2.  Review of treatments that can ameliorate nonadherence in patients with schizophrenia.

Authors:  John M Kane
Journal:  J Clin Psychiatry       Date:  2006       Impact factor: 4.384

3.  Compliance, concordance, adherence.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2007-04       Impact factor: 4.335

4.  Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study.

Authors:  Ashok Malla; Ross Norman; Norbert Schmitz; Rahul Manchanda; Laura Béchard-Evans; Jatinder Takhar; Raj Haricharan
Journal:  Psychol Med       Date:  2006-03-06       Impact factor: 7.723

Review 5.  Utilization of long-acting antipsychotic medication in patient care.

Authors:  John M Kane
Journal:  CNS Spectr       Date:  2006-12       Impact factor: 3.790

Review 6.  Neuroleptics and the natural course of schizophrenia.

Authors:  R J Wyatt
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

7.  Survey of medication adherence in patients with schizophrenia--Korean ADHES data.

Authors:  Sung-Wan Kim; Jin-Sang Yoon; Sung-Ku Choi
Journal:  Hum Psychopharmacol       Date:  2006-12       Impact factor: 1.672

8.  Non-adherence to antipsychotic medication regimens: associations with resource use and costs.

Authors:  Martin Knapp; Derek King; Klaus Pugner; Pablo Lapuerta
Journal:  Br J Psychiatry       Date:  2004-06       Impact factor: 9.319

9.  Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders.

Authors:  Kim A Weiss; Thomas E Smith; James W Hull; A Courtney Piper; Jonathan D Huppert
Journal:  Schizophr Bull       Date:  2002       Impact factor: 9.306

Review 10.  The content and context of compliance.

Authors:  P E Bebbington
Journal:  Int Clin Psychopharmacol       Date:  1995-01       Impact factor: 1.659

View more
  58 in total

1.  Premorbid personality and insight in first-episode psychosis.

Authors:  Maria S Campos; Elena Garcia-Jalon; James K Gilleen; Anthony S David; Victor M D Peralta; Manuel J Cuesta
Journal:  Schizophr Bull       Date:  2010-10-25       Impact factor: 9.306

Review 2.  Nonadherence to immunosuppressive therapy in kidney transplant recipients: can technology help?

Authors:  Erika Nerini; Fulvio Bruno; Franco Citterio; Francesco P Schena
Journal:  J Nephrol       Date:  2016-02-17       Impact factor: 3.902

3.  Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.

Authors:  Jeroen P Koning; Jelle Vehof; Huibert Burger; Bob Wilffert; Asmar Al Hadithy; Behrooz Alizadeh; Peter N van Harten; Harold Snieder
Journal:  Psychopharmacology (Berl)       Date:  2011-07-13       Impact factor: 4.530

4.  Predictors of medication non-adherence in Bulgarian outpatients with schizophrenia.

Authors:  Iglika Vassileva; Vihra Milanova; Turan Asan
Journal:  Community Ment Health J       Date:  2014-01-23

5.  Proposing the Use of Partial AUC as an Adjunctive Measure in Establishing Bioequivalence Between Deltoid and Gluteal Administration of Long-Acting Injectable Antipsychotics.

Authors:  Lik Hang N Lee; Charles Choi; Pavel Gershkovich; Alasdair M Barr; William G Honer; Ric M Procyshyn
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

6.  Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia.

Authors:  Mats O Magnusson; Mahesh N Samtani; Elodie L Plan; E Niclas Jonsson; Stefaan Rossenu; An Vermeulen; Alberto Russu
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

7.  Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study.

Authors:  Qian Cai; Charmi Patel; Edward Kim; Nancy Connolly; Ozgur Tunceli; Antoine C El Khoury
Journal:  Adv Ther       Date:  2019-03-08       Impact factor: 3.845

8.  Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP).

Authors:  José María Pelayo-Terán; Virginia Gajardo Gajardo Galán; Víctor de la Ortiz-García de la Foz; Obdulia Martínez-García; Rafael Tabarés-Seisdedos; Benedicto Crespo-Facorro; Rosa Ayesa-Arriola
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-10-28       Impact factor: 5.270

Review 9.  Paliperidone extended release: a review of its use in the management of schizophrenia.

Authors:  Claudine M Chwieduk; Gillian M Keating
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

Review 10.  Improving treatment adherence in your patients with schizophrenia: the STAY initiative.

Authors:  Fernando Cañas; Koksal Alptekin; Jean Michel Azorin; Vincent Dubois; Robin Emsley; Antonio G García; Philip Gorwood; Peter M Haddad; Dieter Naber; José M Olivares; Georgios Papageorgiou; Miquel Roca
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.